doxazosin has been researched along with Diabetic Angiopathies in 7 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 6.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "Doxazosin is a cost-effective agent when included in a combination therapy in the treatment of hypertension in the diabetic populations of the UK and Italy." | 5.31 | The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. ( Arikian, S; Bustacchini, S; Casciano, J; Casciano, R; Doyle, J; Kim, R; Kopp, Z; Marchant, N, 2001) |
| " We assessed the effects of doxazosin on 24-h BP and spectral analysis of heart rate variability in hypertensive Type 2 diabetic patients with macroalbuminuria and compared the results with those in hypertensive Type 2 diabetic patients with normoalbuminuria and non-diabetic patients with essential hypertension." | 3.73 | Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy. ( Hasegawa, K; Kuji, T; Ogawa, N; Shimura, G; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "Hypertensive NIDDM subjects were treated for 3 months with captopril, nifedipine, or doxazosin." | 2.68 | Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment. ( Canessa, ML; Castellino, P; DeFronzo, RA; Giordano, M; Solini, A, 1997) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 2.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "Doxazosin is a cost-effective agent when included in a combination therapy in the treatment of hypertension in the diabetic populations of the UK and Italy." | 1.31 | The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. ( Arikian, S; Bustacchini, S; Casciano, J; Casciano, R; Doyle, J; Kim, R; Kopp, Z; Marchant, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yasuda, G | 1 |
| Hasegawa, K | 1 |
| Kuji, T | 1 |
| Ogawa, N | 1 |
| Shimura, G | 1 |
| Umemura, S | 1 |
| Tochikubo, O | 1 |
| Giorda, C | 1 |
| Appendino, M | 1 |
| Mason, MG | 1 |
| Imperiale, E | 1 |
| Pagano, G | 1 |
| Giordano, M | 1 |
| Castellino, P | 1 |
| Solini, A | 1 |
| Canessa, ML | 1 |
| DeFronzo, RA | 1 |
| Grzeszczak, W | 1 |
| Calò, L | 1 |
| Davis, PA | 1 |
| Cantaro, S | 1 |
| Bonfante, L | 1 |
| Castrignano, R | 1 |
| Carraro, G | 1 |
| D'Angelo, A | 1 |
| Casciano, J | 1 |
| Doyle, J | 1 |
| Casciano, R | 1 |
| Kopp, Z | 1 |
| Marchant, N | 1 |
| Bustacchini, S | 1 |
| Arikian, S | 1 |
| Kim, R | 1 |
| Feher, MD | 1 |
| Henderson, AD | 1 |
| Wadsworth, J | 1 |
| Poulter, C | 1 |
| Gelding, S | 1 |
| Richmond, W | 1 |
| Sever, PS | 1 |
| Elkeles, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for doxazosin and Diabetic Angiopathies
| Article | Year |
|---|---|
[Use of doxazosin (Cardura-Pfizer), alpha 1-adrenoreceptor antagonist, in treatment of hypertension in patients with diabetes].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Animals; Diabetic Angiopathies; Doxazosin; Humans; Hyperc | 1998 |
4 trials available for doxazosin and Diabetic Angiopathies
| Article | Year |
|---|---|
Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, | 1995 |
Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Antiporters; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; D | 1997 |
Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Coronary Disease; Diabetes Me | 1998 |
Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
Topics: Adrenergic alpha-Antagonists; Aged; Atenolol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1990 |
2 other studies available for doxazosin and Diabetic Angiopathies
| Article | Year |
|---|---|
Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Blood Pre | 2005 |
The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy.
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Do | 2001 |